Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Gastric Adenocarcinoma

Mayo ClinicSmall moleculePhase 3Dormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
73/ 100

Competitive context

65 Active assets in the Gastric Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Boehringer Ingelheim
Phase 3BB
TRASTUZUMAB
Boehringer Ingelheim
Phase 2BB
Eloxatin
Shanghai Zhongshan Hospital
Phase 3BB
Capecitabine
Shanghai Zhongshan Hospital
Phase 3BB
Pembrolizumab
Epkin
Phase 3BB

View all 50 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →